Cargando…
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma
We report a novel group of clinically aggressive spinal cord ependymomas characterized by Grade III histology, MYCN amplification, an absence of NF2 alterations or other recurrent pathogenic mutations, and a unique methylation classifier profile. Seven cases were found to have MYCN amplification in...
Autores principales: | Raffeld, Mark, Abdullaev, Zied, Pack, Svetlana D., Xi, Liqiang, Nagaraj, Sushma, Briceno, Nicole, Vera, Elizabeth, Pittaluga, Stefania, Lopes Abath Neto, Osorio, Quezado, Martha, Aldape, Kenneth, Armstrong, Terri S., Gilbert, Mark R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346356/ https://www.ncbi.nlm.nih.gov/pubmed/32641156 http://dx.doi.org/10.1186/s40478-020-00973-y |
Ejemplares similares
-
MYCN amplification drives an aggressive form of spinal ependymoma
por: Ghasemi, David R., et al.
Publicado: (2019) -
Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
por: Shatara, Margaret, et al.
Publicado: (2021) -
Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma
por: Pratt, Drew, et al.
Publicado: (2020) -
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups
por: Egan, Caoimhe, et al.
Publicado: (2020) -
Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2
por: Merchant, Mythili, et al.
Publicado: (2022)